Drug information provided by: Merative, Micromedex®
Meningococcal diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
The following information applies only to the meningococcal vaccine used for meningococcal bacteria Groups A, C, Y, and W-135. These groups cause nearly all of the meningococcal meningitis cases in the U.S. The vaccine will not protect against infection caused by other meningococcal bacteria groups, such as Group B.
Meningococcal infection can cause life-threatening illnesses, such as meningococcal meningitis, which affects the brain, and meningococcemia, which affects the blood. Some persons with meningococcal meningitis and/or meningococcemia also may die. The rate of these diseases peak in adolescence and early adulthood and are more likely to occur in persons with certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.
Immunization against meningococcal disease is recommended for persons 9 months to 55 years of age who are at risk of getting the disease because:
This vaccine is to be administered only by or under the supervision of your doctor.
Portions of this document last updated: March 01, 2023
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.